Evidence map›Paper›PMID 41079170›Full record

ReviewJournal of the Pediatric Orthopaedic Society of North America2025

Medication-Related Impacts on Pediatric Bone Health.

Charu Jain, Luca Valdivia, Laurel Wong, Sheena C Ranade

Abstract readReview
In one paragraph

Review in Journal of the Pediatric Orthopaedic Society of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Effects of stress on bone health in children.Frontiers in endocrinology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Charu JainIcahn School of Medicine at Mount Sinai, Department of Orthopaedics, New York, NY, USA.
Luca ValdiviaIcahn School of Medicine at Mount Sinai, Department of Orthopaedics, New York, NY, USA.
Laurel WongIcahn School of Medicine at Mount Sinai, Department of Orthopaedics, New York, NY, USA.
Sheena C RanadeIcahn School of Medicine at Mount Sinai, Department of Orthopaedics, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone health during childhood and adolescence is crucial because this is when individuals develop most of their lifetime bone mass. Disruptions in bone metabolism during these years, especially those caused by medications, can have long-lasting effects. Many drugs routinely prescribed to children, including glucocorticoids, antiepileptics, chemotherapeutic agents, and psychotropic medications, have been shown to harm bone development. These effects include lower bone mineral density (BMD), impaired bone growth, and a higher risk of fractures. However, specific medications can help strengthen bones in high-risk children. Bisphosphonates, commonly used in treating osteogenesis imperfecta and glucocorticoid-induced osteoporosis, have proven effective in increasing BMD and lowering fracture rates. These drugs slow bone resorption and are generally well tolerated in children, with few serious long-term side effects. Pediatricians and other child health providers play a key role in identifying children at risk for poor bone health and in implementing preventive strategies. Given the lifelong implications of suboptimal bone health, the purpose of the review is to summarize the skeletal effects of medications, which should be an integral part of pediatric care. Key Concepts: (1) Many commonly prescribed pediatric medications, such as glucocorticoids, antiepileptics, and psychotropics, can significantly impair bone development and increase fracture risk.(2) Medication-induced bone loss in children can occur through multiple mechanisms, including impaired osteoblast activity, altered calcium or vitamin D metabolism, and hormonal disruption.(3) Preventive strategies such as optimizing nutrition, promoting weight-bearing activity, and screening high-risk patients can mitigate bone loss during long-term therapy.(4) Bisphosphonates can be effective in treating pediatric osteoporosis but should be reserved for select cases and managed under the supervision of healthcare providers.(5) Coordination between pediatricians and other healthcare specialists is essential to ensure bone health is considered in the context of chronic medication use.

Indexed as

Medication-induced bone lossPediatric bone healthPediatric osteoporosis

Identifiers

PMID41079170
PMCPMC12513273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.